{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Ren B"],"funding":["National Natural Science Foundation of China","Alzheimer&apos;s Association","Division of Materials Research","Division of Chemical, Bioengineering, Environmental, and Transport Systems"],"pagination":["243-250"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6044715"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["2(1)"],"pubmed_abstract":["Cardiovascular disease (CVD) and Alzheimer's disease (AD) have a mutual cause-and-effect relationship, and they share some common risk factors. Although numerous Food and Drug Administration (FDA)-approved drugs have been developed for CVD treatment, no drugs are clinically available for AD treatment. Given the common disease-causing factors and links between the two diseases and the well-demonstrated drugs for CVD, we propose to re-examine the new potential of the existing CVD drugs as amyloid-β (Aβ) inhibitors. 3-Morpholinosydnonimine hydrochloride (SIN-1) is an FDA-approved drug for inhibiting platelet aggregation in CVD. Herein, we examine the inhibition activity of SIN-1 on the aggregation and toxicity of Aβ<sub>1-42</sub> using combined experimental and computational approaches. Coll"],"journal":["ACS omega"],"pubmed_title":["Identification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor."],"pmcid":["PMC6044715"],"funding_grant_id":["2015-NIRG-341372","1607475","1510099","21528601"],"pubmed_authors":["Wang M","Zheng J","Liang G","Zhang M","Lin Y","Chen H","Hu R","Sun Y","Jia L","Ren B"],"additional_accession":[]},"is_claimable":false,"name":"Identification of a New Function of Cardiovascular Disease Drug 3-Morpholinosydnonimine Hydrochloride as an Amyloid-β Aggregation Inhibitor.","description":"Cardiovascular disease (CVD) and Alzheimer's disease (AD) have a mutual cause-and-effect relationship, and they share some common risk factors. Although numerous Food and Drug Administration (FDA)-approved drugs have been developed for CVD treatment, no drugs are clinically available for AD treatment. Given the common disease-causing factors and links between the two diseases and the well-demonstrated drugs for CVD, we propose to re-examine the new potential of the existing CVD drugs as amyloid-β (Aβ) inhibitors. 3-Morpholinosydnonimine hydrochloride (SIN-1) is an FDA-approved drug for inhibiting platelet aggregation in CVD. Herein, we examine the inhibition activity of SIN-1 on the aggregation and toxicity of Aβ<sub>1-42</sub> using combined experimental and computational approaches. Coll","dates":{"release":"2017-01-01T00:00:00Z","publication":"2017 Jan","modification":"2025-04-05T09:52:25.81Z","creation":"2019-03-26T23:47:32Z"},"accession":"S-EPMC6044715","cross_references":{"pubmed":["30023514"],"doi":["10.1021/acsomega.6b00397"]}}